Healthcare
Live Price
Offline$0.1631
+8.73% today
1Y Change
-32.60%
Window
Jun 20, 2025 → Jun 15, 2026
Coverage: 254 bars · Jun 20, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Viva Biotech Holdings (VBIZF) is a Healthcare stock with a market cap of $3.11B and listed on OTC. The stock last traded around $0.16 and down 32.6% across the available one-year price window (Jun 20, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -15.2%, EPS growth of +27.7%, a dividend yield of 0.0%. What stands out right now is revenue -15.2%, EPS +27.7%, free cash flow -51.7% with operating margin 11.2% and ROIC 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 6.4 and price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VBIZF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VBIZF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VBIZF Max Drawdown
-65.07%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VBIZF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$697.0M
-66.9% YoY
FY Net Income
-$386.9M
-234.5% YoY
Free Cash Flow
-$549.4M
-12.7% YoY
Revenue Growth
-15.2%
EPS Growth
+27.7%
Gross Margin
37.9%
Net Margin
12.7%
Income statement
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.0B | 2.2B | 2.4B | 2.1B | 697M |
| Gross Profit | 687M | 738M | 816M | 651M | 305M |
| Operating Income | 270M | 193M | 269M | 237M | 116M |
| EBITDA | 563M | 391M | 436M | 370M | 164M |
| Net Income | 167M | -116M | -528M | 288M | -387M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 942M | 1.0B | 679M | 801M | 2.3B |
| Total Assets | 7.1B | 7.4B | 7.9B | 8.0B | 8.2B |
| Total Liabilities | 3.2B | 3.8B | 4.3B | 4.1B | 4.4B |
| Shareholder Equity | 3.8B | 3.7B | 3.6B | 3.9B | 3.8B |
| Total Debt | 1.3B | 1.9B | 2.8B | 2.7B | 3.0B |
| Net Debt | 342M | 867M | 2.1B | 1.9B | 661M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
43M
-44.5% YoY
Capital Expenditures
593M
-4.9% YoY
Free Cash Flow
549M
-12.7% YoY
Key ratios
Gross Margin
37.9%
Operating Margin
11.2%
Net Margin
12.7%
ROE
5.5%
Debt / Equity
0.33x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.